




Physician-Founded. Patient-Focused.



ABOUT VIREO

Vireo Growth Inc. which operates through its subsidiary, Vireo Health, is a public company, listed on the Canadian Securities Exchange (the “CSE”) and quoted on the OTCQX under the ticker symbols “VREO” and “VREOF”.

VIREO’S MEDICAL FOCUS

Vireo is a physician-founded, patient-focused company that integrates best-in-class medical, scientific, and engineering practices into the development of its products and patient care practices. Vireo’s founder, Kyle Kingsley, MD, is a board-certified emergency medicine physician, serial entrepreneur, and inventor. He was inspired to launch Vireo after encountering numerous patients who successfully used cannabis to effectively alleviate their pain and suffering. Vireo’s team includes physicians, scientists, and horticulturists that have been successful in a variety of settings and who bring a broad spectrum of experience in best practices and evidence-based medicine. Vireo is driven to

VIREO’S FOCUS ON RESEARCH

High-quality research is the key for Vireo in reaching its goals as a business. The opportunity for Vireo to expand its research focus through this Research Partnership with University of Pittsburgh School of Medicine is highly attractive and represents a strong strategic fit.

VIREO’S FINANCIAL PERFORMANCE & MARKET CAPITALIZATION

Vireo is consistently ranked at the top of the industry in the credit rankings from Viridian Capital Advisors (a premiere analyst in the cannabis industry) benefitting from very low debt leverage compared with its peers. Vireo posted third quarter 2025 revenue of \$91.7M, and profitability of \$25.4M. Through the nine months ended September 30, 2025, Vireo delivered \$164.3M and \$45.2M in Adjusted EBITDA. Vireo’s market capitalization as of February 2026 is \$556.1M.

VIREO’S OPERATIONAL FOOTPRINT

The Company operates cultivation, production, and dispensary facilities in _____ States. Pennsylvania is Vireo’s current focus for strategic expansion.

\$ FINANCIAL PERFORMANCE

MARKET CAP (FEB 2026)

\$556.1M

Q3 2025 REVENUE

\$91.7M

Q3 2025 PROFITABILITY

\$25.4M

9 MONTHS ENDED SEPT 30, 2025

Revenue: **\$164.3M**

Adj. EBITDA: **\$45.2M**

Ranked **top of industry** in credit rankings from Viridian Capital Advisors with very low debt leverage.

 CSE: VREO

 OTCQX: VREOF